Hangzhou Zhongmei Huadong Pharmaceutical

• NCT07805551

  Phase 1/2, Recruiting, 220 people, 4 Sept 2026

• NCT07521631

  Phase 2, Recruiting, 372 people, 13 Apr 2026

• Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin

  Phase 1, Not yet recruiting, 42 people, 30 Mar 2026

• NCT07417306

  Phase 3, Not yet recruiting, 912 people, 18 Feb 2026

• A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin

  Phase 1, Recruiting, 111 people, 9 Jan 2026

• Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control

  Phase 4, Recruiting, 430 people, 24 Nov 2025

• NCT07124936

  Phase 1/2, Recruiting, 97 people, 15 Aug 2025

• NCT07109700

  Phase 2, Recruiting, 216 people, 7 Aug 2025

• NCT07082114

  Phase 3, Recruiting, 800 people, 24 Jul 2025

• NCT07036172

  Phase 3, Recruiting, 460 people, 25 Jun 2025

• NCT06739044

  Phase 3, Completed, 494 people, 18 Dec 2024

• NCT06634927

  Phase 1, Completed, 68 people, 10 Oct 2024

• NCT06601517

  Phase 1, Status unknown, 30 people, 19 Sept 2024

• NCT06501326

  Collaborator, Phase 4, Status unknown, 102 people, 15 Jul 2024

Sources: clinicaltrials.gov

• Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HDM1005)—A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose-Escalation Study

  ADA Scientific Sessions 2025 abstract, 13 Jun 2025